Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy

This publication has 19 references indexed in Scilit:

• Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy
  Journal of Clinical Oncology, 1999
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
  Journal of Clinical Oncology, 1998
• Bcl-2 Overexpression and Smoking History in Head and Neck Cancer
  JNCI Journal of the National Cancer Institute, 1995
• Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies
  Blood, 1995
• Purification and Characterization of the Bcl-2 Protein
  Archives of Biochemistry and Biophysics, 1994
• The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in Lymph Node-Negative Breast Cancer Patients
  JNCI Journal of the National Cancer Institute, 1994
• Expression of bcl‐2 gene product in neuroblastoma
  The Journal of Pathology, 1994
• All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
  Blood, 1991
• DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene.
  Proceedings of the National Academy of Sciences, 1987
• Distinctive Chromosomal Abnormalities in Histologic Subtypes of Non-Hodgkin's Lymphoma
  New England Journal of Medicine, 1982